By Judy George, Deputy Managing Editor, MedPage Today
October 24, 2026
The frontier of multiple sclerosis (MS) treatment, characterized by the emergence of chimeric antigen receptor (CAR) T-cell therapies, has hit a somber milestone. During the Phase I "Breakfree-2" clinical trial, an experimental CD19-directed CAR T-cell therapy known as zolacabtagene autoleucel (zola-cel) demonstrated promising potential for inducing long-term "immune resets" in patients with highly active relapsing and progressive MS. However, these clinical aspirations have been tempered by the death of a trial participant, a development that has prompted a reevaluation of safety protocols in the burgeoning field of autoimmune CAR T-cell research.
The fatality, which occurred 44 days after the administration of zola-cel, has cast a spotlight on the complexities of managing intensive immunotherapy in patients who have exhausted traditional disease-modifying therapies (DMTs). While the therapy has shown remarkable efficacy in early-stage data, the death serves as a stark reminder of the significant risks associated with the aggressive conditioning regimens required for these treatments.
The Chronology of a Fatal Complication
The details surrounding the participant’s decline were presented by Jeffrey Cohen, MD, of the Cleveland Clinic Mellen Center, at MSToronto2026—a joint meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS).
According to the report, the patient, who had been diagnosed with highly active relapsing MS, received the zola-cel infusion as part of the study protocol. The first clinical warning signs emerged on day 17, when the patient began to exhibit extrapyramidal motor symptoms, specifically tremors and muscular rigidity. The medical team responded with a standard intervention of intermittent corticosteroids and intravenous immunoglobulin (IVIG) to manage the neurological manifestations.
By day 41, the patient’s condition remained concerning. Clinicians, unable to identify a definitive cause for the ongoing neurological issues and seeking to curb the activity of circulating CAR-T cells, administered a dose of high-dose cyclophosphamide. It is important to note that cyclophosphamide was a component of the original treatment protocol; its re-administration in this specific instance was an attempt to mitigate what was perceived as a potential over-activation of the immune system.
Tragically, the intervention did not produce the desired outcome. On day 43, the patient developed septic pneumonia. Despite intensive care efforts, the patient passed away on day 44. Dr. Cohen emphasized that the pathogenesis of the event remains under active investigation. Notably, the patient’s CAR-T cell expansion levels were consistent with those observed in other successful study participants, suggesting that the fatality was not a result of "runaway" cell expansion, but rather a complex interplay of immune suppression and secondary infection.
Supporting Data: Efficacy Amidst Safety Concerns
Despite this fatal Grade 5 event, the broader data from the Breakfree-2 study paints a picture of a potent therapeutic candidate. The study, which included 66 patients (30 with highly active relapsing MS and 36 with progressive MS), focused on testing two distinct dose levels of zola-cel.
Efficacy Indicators
The secondary endpoints of the trial suggested that zola-cel could fundamentally alter the course of MS:
- DMT Independence: At the time of the last follow-up, all 60 patients treated at the higher dose level remained off traditional disease-modifying therapies. This included a subset of nine patients who had been monitored for over 12 months, indicating a potential for durable remission.
- NEDA Achievement: Six out of seven patients with highly active relapsing MS who were evaluated for "No Evidence of Disease Activity" (NEDA) met the criteria at or after week 26.
- Progressive MS Stability: In the progressive MS cohort, MRI scans showed no new disease activity. Furthermore, despite baseline disability progression, 92% of these patients experienced either stability or clinical improvement in their mobility and neurological function.
Safety and Tolerability
The safety profile, excluding the single fatal event, was largely consistent with established expectations for CAR T-cell therapies:
- Cytokine Release Syndrome (CRS): Approximately 42.4% of participants experienced CRS. However, these cases were predominantly mild, with 36.4% classified as Grade 1 and 6.1% as Grade 2. Median time to resolution was a manageable 2 days.
- Neurotoxicity (ICANS): Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 7.6% of patients. Most were low-grade, resolving in 2 days. One Grade 4 event in a patient with progressive MS was successfully managed with corticosteroids and anakinra (Kineret), resolving within four days.
Official Responses and Industry Context
The death occurred just as the broader industry was grappling with heightened safety oversight. In September, Bristol Myers Squibb (BMS), the developer of zola-cel, initiated a voluntary pause of its zola-cel program. This decision coincided with reports from Novartis regarding three fatal cases of ICANS in their own trials involving rapcabtagene autoleucel (rap-cel).
Dr. Cohen was quick to clarify that the death in the zola-cel trial was distinct from the ICANS-related fatalities reported by competitors. "The death in the zola-cel study was not related to ICANS," he stated, reinforcing that the underlying cause in this specific patient appears to be linked to the infectious complications following intensive lymphodepletion and salvage therapy.
When questioned about the future of the program, Dr. Cohen emphasized the need for nuance. "We’re still learning some of the nuances of CAR-T therapy. They can’t all be lumped together. Each cell product is a little bit different, and they have their own attributes," he noted.
The Broader Implications for MS Treatment
The allure of CAR T-cell therapy in neurology lies in the ability to "reset" the immune system. By targeting CD19-positive B cells, the therapy can achieve a deep depletion of the very cells that drive the inflammatory damage in MS. Once these cells are cleared, the body’s immune system reconstitutes, potentially eliminating the autoreactive cells that have plagued the patient for years.
However, the Breakfree-2 experience highlights a critical tension in modern medicine: the trade-off between the potential for a "functional cure" and the risks inherent in deep immune system manipulation.
Interpreting Efficacy
Dr. Cohen provided a necessary caveat for the clinical community: "There’s some enticing evidence of benefit, although these trials are still small with relatively short follow-up, and for the most part, are uncontrolled and open-label. So, efficacy results have to be interpreted with caution."
The clinical community now faces several pressing questions:
- Conditioning Regimens: Should the lymphodepletion protocols (using fludarabine and cyclophosphamide) be adjusted to reduce the risk of secondary infections, such as septic pneumonia?
- Patient Selection: Are there biomarkers that can identify patients who are at higher risk for severe complications before they undergo the infusion?
- Standardization: As more manufacturers enter the space, will regulators require more stringent, uniform safety guidelines for autoimmune CAR-T trials compared to those used in oncology?
Conclusion
The case of the patient who passed away at day 44 of the Breakfree-2 study serves as a somber inflection point for the research community. While the data suggests that zola-cel is a powerful tool capable of halting disease progression in a population with few remaining options, the fatality highlights the precarious balance of safety in high-intensity immunotherapy.
As the program remains under evaluation, the medical community will be watching closely to see how developers, including BMS, refine their protocols. The promise of an "immune reset" remains one of the most exciting prospects in MS research, but as this trial has demonstrated, the path to clinical success must be paved with an uncompromising commitment to patient safety and a deeper understanding of the complex, systemic biological reactions triggered by these advanced therapies. For now, the clinical trials of zola-cel continue to provide a blueprint for both the potential—and the peril—of the next generation of MS medicine.
